GT Biopharma Inc GTBP 深 沪
等待开盘 02-04 09:30:00 美东时间
0.522
+0.012
+2.29%
华盛通- 最 高0.5455
- 今 开0.5171
- 成交量 613.11万股
- 最 低 0.486
- 昨 收 0.5103
- 总市值 555.20万
- 52周最高 3.85
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 0.4011
- 委 比 87.50%
- 总股本 1063.61万
- 历史最高 591.99
- 量 比 4.59
- 振 幅 11.66%
- 历史最低 0.4011
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GT Biopharma Receives FDA Clearance Of Investigational New Drug Application For GTB-5550 TriKE
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026Phase 1 protocol allows multiple solid tumor types known to express B7-H3Unaudited proforma cash balance as of January 31, 2026 of approximately
02-03 21:33
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers AstraZeneca PLC Ordinary Shares (NYSE:AZN) stock rose 107.1% to $192.1...
02-03 01:05
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment towa...
01-16 21:00
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.
01-15 21:01
EXCLUSIVE: GT Biopharma Announces IND Submission For GTB-5550 TriKE; Reports Preliminary Unaudited Cash Balance Of ~$7M As Of Dec. 31, 2025
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H3 TrikePreliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extendGT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H3 Trike
01-15 21:00
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GT Biopharma submitted an IND application for GTB-5550, a B7-H3-targeted NK cell engager, to treat B7-H3-expressing solid tumors. The company aims to initiate a Phase 1 basket trial in 2026. GTB-5550 uses a TriKE platform combining anti-CD16, WT IL-15, and anti-B7-H3 nanobodies to activate NK cells. The trial will assess safety and tolerability across seven cancer types, with subcutaneous dosing over five days per week. The global market for B7-H...
01-15 13:30
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
2025-12-19 20:55
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
2025-12-11 23:17
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
2025-12-06 05:05
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia ...
2025-12-05 01:20
